Welcome to BioBridge®
Consultants in Building Business from Bioscience Innovation for over 35 years. The founder, Meredith Lloyd-Evans, is now moving towards retirement, focusing on one or two very long-standing clients. We are still open to approaches from companies looking to license their developments into Japan, especially new dermatology products for unmet needs, likely to be prescription-only rather than over-the-counter. Improvements on current topical products are still needed for many conditions. Our past portfolio has been very wide, including industry (of all sizes), individuals, equity companies, universities, governments, research institutes and public bodies, involved in healthcare, biotechnology, medical devices, biomaterials, agricultural resources, animal health, green industries, marine biotechnology and food.
Featured News
BioBridge evolves!
April 2024: BioBridge celebrates 35 years of work as an independent biosciences innovation consultancy.
October 2024: BioBridge welcomes Sophie Williams of Sophos Science onto the team, to provide support to our long-standing dermatological pharma client.
December 2024: Sue Addison retires after almost 20 years of much-valued service - she started as a temp bringing our marketing database up-to-date and finished as PA and Project Co-ordinator.
November 2025: BioBridge welcomes Dr Lydia Lee into the team, recognising the increasing importance of activies in China in a wide range of bioscience innovation areas.
Sophie Williams holds a BSc degree in Chemistry and Oceanography from the University of Swansea. Her research has been conducted in a number of companies, including Schering Agrochemicals, Pfizer Global R&D, UCB Celltech and Domainex. She is a synthetic chemist, for which she has received several awards, and has specialised in new active ingredients and therapies for multiple sclerosis. She has made significant contributions to synthesis and physicochemical knowledge in the areas of G-protein coupled receptors, ion channel receptors, kinases and other enzyme targets. Most recently, she founded Sophos Science to make her expertise in project management more widely available.
Lydia Lee holds an MSci degree in Natural Sciences (Chemistry) with first-class honours and a PhD in Chemistry from the University of Cambridge. Her doctoral research focused on natural products and synthesis of the aplyronines as promising anticancer agents. During her time at Cambridge, she received multiple scholarships and academic awards for outstanding achievement, followed by research positions in medicinal chemistry and early-stage drug discovery at Astex Pharmaceuticals and Domainex Limited, specialising in small-molecule therapeutics discovery in oncology and cardiovascular diseases. She is author of a number of scientific publications and patents arising from this work. In 2020, Lydia founded Oxbridge Gateway Limited, an EdTech and educational consultancy she leads as Chief Executive Officer, offering personalised mentoring programmes to support students in higher education and career development. Currently, she also serves as Vice President of Strategic Investment at Asia-Pacific City Medical Group Limited, leading medical technology transfer initiatives and establishing collaborations with high-value biotechnology ventures. Lydia is a careers mentor at Jesus College, Cambridge, and for the Royal Society of Chemistry, of which she is a member. She is also a member of the Chartered Management Institute.
